TNFRSF13C and myasthenia gravis: Recent experimental report showed dose-dependent, immunomodulatory distant effect resulting from BAFF receptor-specific mAb-siRNA-conjugate treatment in an in vivo model of MG (Ibtehaj and Huda 2017).